Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. has submitted a rolling submission to the U.S. Food and Drug Administration (FDA) for Xocova as a prevention measure against COVID-19.

Apr 01, 2025

Professor Hirofumi Sawa, Director of the IVReD, and Visiting Professor Akihiko Sato, Clinical Development Division, were involved in the development of the first domestically produced new coronavirus treatment, “Xocova”. Shionogi & Co., Ltd. has submitted a rolling submission to the U.S. Food and Drug Administration (FDA) for Xocova as a prevention measure against COVID-19, starting on March 31, 2025 (U.S. time). Please see the page below for details.